DMC BIOTECHNOLOGIES, INC.
BOULDER, CO · Founded 2017 · CIK 0001728411 · Biotech · Private
Synthetic Metabolic Valves (SMV) — a metabolic engineering platform using inducible enzyme degradation and gene silencing to dynamically control microbial metabolism for decoupled growth and product f
dmcbio.com →- Grants
- $341K
- 2 awards
- Sector median: 1
- Raised
- $47M
- 8 Form D · Dec 2025
- 10 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 0 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · STTR Phase I: Commercialization of Synthetic Metabolic Valves | $241,250 | |
| Federal grant | Department of Agriculture · Dynamic Metabolic Control For The Production Of Limonene | $100,000 | |
| Private capital raised | Form D · SEC | $1,166,666 | |
| Private capital raised | Form D · SEC | $4,649,995 | |
| Private capital raised | Form D · SEC | $22,446 | |
| Private capital raised | Form D · SEC | $33,760,493 | |
| Private capital raised | Form D · SEC | $66,720 | |
| Private capital raised | Form D · SEC | $4,791,203 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $1,414,267 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $904,500 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1197 | Khartis Therapeutics | — | — |
| 1198 | TATEVA THERAPEUTICS INC. | — | — |
| 1199 | AIMMAX THERAPEUTICS INC | — | $200K |
| 1200 | DMC BIOTECHNOLOGIES, INC. | — | $47M |
| 1201 | Obatala Sciences, Inc. | — | $200K |
| 1202 | Oncorus, Inc. | — | $47M |
| 1203 | Qlaris Bio, Inc. | — | $42M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Josko BobanovicDirector
- Doug CameronDirector
- Alastair CooperDirector
- Jim FlattDirector · Executive Officer
- Carolyn FritzDirector
- Ashley JenkinsExecutive Officer
- K'Lynne JohnsonDirector
- Matthew LipscombDirector · Executive Officer
- Michael LynchDirector
- Rob van der MeijDirector
- Josh YelenExecutive Officer
Patents
- Mevalonate Derivatives And Methods For Making The Sameapplication
- Methods And Microorganisms For Production Of A Product Using Ethanol As A Carbon Sourceapplication
- Methods And Microorganisms For Production Of A Product Using Ethanol As A Carbon Sourceapplication
- Mevalonate Lactone Derivativesapplication
- Methods and Microorganisms for Production of a Product Using Ethanol as a Carbon Sourceapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.